Territorial Availability: Available through Bertin Technologies only in France
- Correlated keywords
- CD-22 BLCAM Siglec2 TCell Leu14 anti-body LL-2 EPB2 antiCD22 IgC-2 SHP1
- Product Overview:
CD22 is a transmembrane receptor and member of the sialic acid-binding immunoglobulin-type (Ig-type) lectin (SIGLEC) family.{65416,13652} It is composed of N-terminal extracellular Ig-like variable (IgV) and Ig-like constant 2 (IgC2) domains, a membrane-spanning region, and an intracellular immunoreceptor tyrosine-based inhibitory motif (ITIM) domain. CD22 has two isoforms formed via alternative splicing, CD22?, which is the full-length form and contains six IgC2 domains, and CD22?, which lacks the third and fourth IgC2 domains. It is expressed in the cytosol of premature B cells and on the cell surface of resting and activated B lymphocytes but is not expressed in differentiated B cells.{65417} CD22 is an inhibitory receptor activated by binding of ?2,6-linked sialic acid-containing molecules, such as glycoproteins, which stimulates phosphorylation of tyrosine in the ITIM domain, leading to recruitment of Src homology 2 domain-containing phosphatases (SHPs), including SHP-1, spleen tyrosine kinase (Syk), LYN, and PI3K.{65416,13652} Knockout of Cd22 decreases IgG1 titers in mice immunized with OVA/alum and expression of human CD22 in Cd22 -/- mice rescues this phenotype.{65418} CD22 is overexpressed in cancer cells isolated from patients with hairy cell leukemia.{65417} Cayman’s CD22 Chimeric Monoclonal Antibody was produced recombinantly from the humanized EPB-2/LL2 antibody sequence and can be used for flow cytometry (FC) and immunoprecipitation (IP) applications. The humanized EPB-2/LL2 antibody was generated by fusing human IgG1 constant domains to the antigen-binding domain of the anti-CD22 mouse monoclonal antibody, EPB-2/mLL2.{66217,66218}
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.